NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NINDS E-143-2002-1-LU-67 Method For the Treatment of Multiple Sclerosis LU EP 10182563.6 Abandoned
NINDS E-143-2002-1-NL-69 Method For the Treatment of Multiple Sclerosis NL EP 10182563.6 Abandoned
NINDS E-143-2002-1-MC-68 Method For the Treatment of Multiple Sclerosis MC EP 10182563.6 Abandoned
NINDS E-143-2002-1-GB-62 Method For the Treatment of Multiple Sclerosis GB EP 10182563.6 Abandoned
NINDS E-143-2002-1-CH-53 Method For the Treatment of Multiple Sclerosis CH EP 10182563.6 Abandoned
NINDS E-143-2002-1-TR-75 Method For the Treatment of Multiple Sclerosis TR EP 10182563.6 Abandoned
NINDS E-143-2002-1-EP-12 Method For the Treatment of Multiple Sclerosis EP DIV 10182563.6 Abandoned
NINDS E-143-2002-1-HU-64 Method For the Treatment of Multiple Sclerosis HU EP 10182563.6 Abandoned
NINDS E-143-2002-1-IE-65 Method For the Treatment of Multiple Sclerosis IE EP 10182563.6 Abandoned
NINDS E-143-2002-1-IT-66 Method For the Treatment of Multiple Sclerosis IT EP 10182563.6 Abandoned
NINDS E-143-2002-1-GR-63 Method For the Treatment of Multiple Sclerosis GR EP 10182563.6 Abandoned
NINDS E-143-2002-1-DE-56 Method For the Treatment of Multiple Sclerosis DE EP 10182563.6 Abandoned
NINDS E-143-2002-1-FI-60 Method For the Treatment of Multiple Sclerosis FI EP 10182563.6 Abandoned
NINDS E-143-2002-1-FR-61 Method For the Treatment of Multiple Sclerosis FR EP 10182563.6 Abandoned
NINDS E-143-2002-1-SE-72 Method For the Treatment of Multiple Sclerosis SE EP 10182563.6 Abandoned
NINDS E-143-2002-1-SK-74 Method For the Treatment of Multiple Sclerosis SK EP 10182563.6 Abandoned
NINDS E-143-2002-1-SI-73 Method For the Treatment of Multiple Sclerosis SI EP 10182563.6 Abandoned
NINDS E-143-2002-1-RO-71 Method For the Treatment of Multiple Sclerosis RO EP 10182563.6 Abandoned
NINDS E-143-2002-1-PT-70 Method For the Treatment of Multiple Sclerosis PT EP 10182563.6 Abandoned
NINDS E-143-2002-1-ES-59 Method For the Treatment of Multiple Sclerosis ES EP 10182563.6 Abandoned
NINDS E-143-2002-1-BE-51 Method For the Treatment of Multiple Sclerosis BE EP 10182563.6 Abandoned
NINDS E-143-2002-1-BG-52 Method For the Treatment of Multiple Sclerosis BG EP 10182563.6 Abandoned
NINDS E-143-2002-1-AT-50 Method For the Treatment of Multiple Sclerosis AT EP 10182563.6 Abandoned
NINDS E-143-2002-1-EP-03 Method For the Treatment of Multiple Sclerosis EP National Stage 03762181.0 Abandoned
NINDS E-143-2002-1-CA-06 Method For the Treatment of Multiple Sclerosis CA National Stage 2490186 Abandoned
NINDS E-143-2002-1-AU-05 Method For the Treatment of Multiple Sclerosis AU National Stage 2003247813 Abandoned
NHLBI E-160-2002-0-AU-06 Trypotophan as a Functional Replacement for ADP-Ribose-Arginine in Recombinant Proteins AU National Stage 2003247826 Abandoned
NINDS E-143-2002-1-US-02 Method For the Treatment of Multiple Sclerosis US ORD 10/607,598 7258859 Abandoned PDF
NHLBI E-160-2002-0-PCT-02 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins PCT PCT PCT/US2003/020498 Expired
NINDS E-143-2002-1-PCT-01 Method For the Treatment of Multiple Sclerosis PCT PCT COMB PCT/US2003/020428 Expired
NHLBI E-160-2002-0-EP-04 Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins EP National Stage 03762212.3 Abandoned
NIDDK E-264-2003-0-US-01 Pyridinium Compounds To Treat Cystic Fibrosis And Other IL-8 Dependent Disorders US 60/482,764 Abandoned
NHLBI E-160-2002-0-CA-05 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins CA National Stage 2490290 Abandoned
NINDS E-143-2002-1-CA-45 Method For the Treatment of Multiple Sclerosis CA DIV 2844639 Abandoned
NINDS E-143-2002-1-IL-46 Method For the Treatment of Multiple Sclerosis IL DIV 241920 Abandoned
NCI E-013-2002-0-CA-06 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors CA National Stage 2490659 Abandoned
NCI E-013-2002-0-EP-04 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors EP National Stage 03762161.2 Abandoned
NCI E-013-2002-0-GB-12 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors GB EP 03762161.2 Abandoned
NCI E-013-2002-0-FR-11 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors FR EP 03762161.2 Abandoned
NCI E-013-2002-0-DE-10 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors DE EP 03762161.2 Abandoned
NCI E-013-2002-0-AU-05 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors AU National Stage 2003248744 Abandoned
NCI E-040-1996-0-US-08 METHODS AND COMPOSITIONS FOR TRANSFORMING DENDRITIC CELLS AND ACTIVATING T CELLS US DIV 10/607,327 7378277 Expired PDF
NHLBI E-211-2002-0-PCT-02 Il-21 Critically Regulates Immunoglobulin Production PCT PCT PCT/US03/20370 Abandoned
NCI E-262-2000-1-PCT-02 SH2 Domain Binding Inhibitors PCT PCT PCT/US03/19987 Expired
NCI E-013-2002-0-PCT-02 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors PCT PCT PCT/US03/20367 Expired
NCI E-286-2000-0-US-07 Histone Deacetylase Inhibitors in Diagnosis and Treatment of Thyroid Neoplasms US National Stage 10/250,320 Abandoned
NIDDK E-202-2003-0-US-01 Adenosine Derivatives As A3 Receptor Agonists US 60/482,459 Abandoned
NCI E-090-2001-0-US-04 Hexahydrofuro[2,3-B]furan-3-yl-n{3[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl) amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor US CON 10/606,342 7157495 Expired PDF
NCI E-232-1998-0-US-03 Methods for Identifying Modulators of GADD45 Polypeptide Activity US DIV 10/600,158 7005419 Abandoned PDF
NHGRI E-331-2003-0-US-01 Method For The Treatment Of Hypertension US 60/280,422 Abandoned